TG Therapeutics (NASDAQ:TGTX) Rating Reiterated by LADENBURG THALM/SH SH

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reiterated by LADENBURG THALM/SH SH in a report released on Thursday, Benzinga reports. They presently have a $39.00 price target on the biopharmaceutical company’s stock. LADENBURG THALM/SH SH’s target price points to a potential upside of 173.68% from the company’s previous close.

A number of other analysts have also recently issued reports on the company. StockNews.com cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. B. Riley lifted their price objective on TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of TG Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.00.

TG Therapeutics Stock Up 3.1 %

Shares of TG Therapeutics stock traded up $0.43 during midday trading on Thursday, hitting $14.25. The company’s stock had a trading volume of 1,905,647 shares, compared to its average volume of 4,174,303. The firm has a market capitalization of $2.20 billion, a P/E ratio of 712.86 and a beta of 2.30. The stock has a 50-day simple moving average of $15.14 and a 200-day simple moving average of $13.87. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. The business had revenue of $43.97 million during the quarter, compared to analysts’ expectations of $40.06 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. During the same quarter last year, the firm posted ($0.39) earnings per share. As a group, sell-side analysts expect that TG Therapeutics will post -0.12 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently made changes to their positions in TGTX. Advisor Group Holdings Inc. increased its stake in shares of TG Therapeutics by 49.5% in the first quarter. Advisor Group Holdings Inc. now owns 34,433 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 11,406 shares during the period. Raymond James & Associates increased its stake in shares of TG Therapeutics by 4.3% in the first quarter. Raymond James & Associates now owns 165,994 shares of the biopharmaceutical company’s stock worth $1,579,000 after purchasing an additional 6,860 shares during the period. HighTower Advisors LLC increased its stake in TG Therapeutics by 28.3% during the first quarter. HighTower Advisors LLC now owns 13,603 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,998 shares during the period. MetLife Investment Management LLC increased its stake in TG Therapeutics by 59.0% during the first quarter. MetLife Investment Management LLC now owns 71,269 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 26,443 shares during the period. Finally, BlackRock Inc. increased its stake in TG Therapeutics by 0.4% during the first quarter. BlackRock Inc. now owns 8,935,578 shares of the biopharmaceutical company’s stock valued at $84,978,000 after acquiring an additional 33,413 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.